EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Dysregulated proline metabolism contributes to retinal fibrosis in neovascular AMD: Therapeutic potential of prolyl-4-hydroxylase inhibition

Yue Zeng, Ting Zhang, Elisa Cornish, So-Ra Lee, Michelle Yam, Mark Eminhizer, Jingwen Zeng, Jialing Zhang, Shaoxue Zeng, Azhar Dzulhadj B Arafah, Xian Wei, Jinliang Yang und 6 weitere

Molecular Therapy · 2026-10 · 34 (10) · 6111-6133

DOI: 10.1016/j.ymthe.2026.07.044 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Therapy, 2026-10. Verfasst von Yue Zeng und 17 weiteren Autor:innen. Beteiligte Einrichtung: The Department of Ophthalmology and Research Laboratory of Macular Disease, West China Hospital, Sichuan University, Chengdu 610041, China; Save Sigh…. Hauptthemen laut MEDLINE: Prolyl-Hydroxylase Inhibitors, Macular Degeneration, Proline, Prolyl Hydroxylases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Eye Institute, The International Retinal Research Foundation Inc, National Health and Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Subretinal fibrosis, a major cause of irreversible vision loss in neovascular age-related macular degeneration (nAMD), is driven by excessive deposition of extracellular matrix such as collagens. While proline metabolism is known to play a critical role in collagen biosynthesis and fibrosis, its involvement in subretinal fibrosis remains unclear. Here, we characterized the progression of fibrovascular lesions in JR5558 mice, observing significant molecular alterations as early as 4 weeks of age and phenotypic changes by 8 weeks. Transcriptomic and metabolomic analyses revealed elevated levels of 4-hydroxyproline, an essential component of collagen, alongside significant alterations of other fibrosis-related pathways. P4HA1, a catalytic subunit of prolyl-4-hydroxylase essential for 4-hydroxyproline biosynthesis, was prominently expressed in fibrotic lesions in retinas of JR5558, laser-induced murine models and human eyes with nAMD. Targeting P4HA1 with the small-molecule inhibitor diethyl pythiDC significantly attenuated fibrovascular lesion expansion in the JR5558 mouse model and reduced collagen turnover in human retinal pigment epithelium cells. Treatment responses in JR5558 mice were lesion cluster dependent, with the combination of diethyl pythiDC with aflibercept showing selective antifibrotic benefit in moderate lesion cluster. These findings support a potential role of proline metabolism, particularly proline hydroxylation, in subretinal fibrosis. Inhibiting P4HA1 with diethyl pythiDC inhibited fibrosis in the models we studied, highlighting a potential therapeutic strategy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prolyl-Hydroxylase InhibitorsMacular DegenerationProlineProlyl HydroxylasesProcollagen-Proline DioxygenaseRetinaAnimalsMiceHumansFibrosisDisease Models, AnimalRetinal Pigment EpitheliumCollagen

Stichwörter der Autor:innen

4-hydroxyprolineJR5558 mouse modelP4HA1diethyl pythiDCneovascular age-related macular degenerationproline metabolismprolyl 4-hydroxylasesubretinal fibrosis

Substanzen

Prolyl-Hydroxylase InhibitorsProlineProlyl HydroxylasesProcollagen-Proline DioxygenaseCollagen

Autor:innen und Institutionen

  • The Department of Ophthalmology and Research Laboratory of Macular Disease, West China Hospital, Sichuan University, Chengdu 610041, China; Save Sight Institute, Faculty of Medicine and Health, The University of Sydney,…
  • Save Sight Institute, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2000, Australia. Electronic address: ting.zhang@sydney.edu.au.
  • Save Sight Institute, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2000, Australia.
  • Departments of Ophthalmology and Visual Sciences and Biochemistry and Molecular Medicine, West Virginia University, Morgantown, WV 26506, USA.
  • Department of Biotherapy, Cancer Center, State Key Laboratory of Biotherapy/Collaborative Innovation Center for Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China.
  • Save Sight Institute, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2000, Australia; New South Wales Tissue Bank, Sydney Eye Hospital, New South Wales Organ and Tissue Donation Service, Sydney, N…

Förderung

  • National Eye Institute
  • The International Retinal Research Foundation Inc
  • National Health and Medical Research Council

Zitieren

APA

Zeng, Y., Zhang, T., Cornish, E., Lee, S. R., Yam, M., Eminhizer, M., Zeng, J., Zhang, J., Zeng, S., Arafah, A. D. B., Wei, X., Yang, J., Zhu, M., Chang, A., Zhang, M., Du, J., Zhu, L., & Gillies, M. C. (2026). Dysregulated proline metabolism contributes to retinal fibrosis in neovascular AMD: Therapeutic potential of prolyl-4-hydroxylase inhibition. Molecular Therapy, 34(10), 6111-6133. https://doi.org/10.1016/j.ymthe.2026.07.044

Vancouver

Zeng Y, Zhang T, Cornish E, Lee SR, Yam M, Eminhizer M, et al. Dysregulated proline metabolism contributes to retinal fibrosis in neovascular AMD: Therapeutic potential of prolyl-4-hydroxylase inhibition. Molecular Therapy. 2026;34(10):6111-6133. doi:10.1016/j.ymthe.2026.07.044

BibTeX
@article{Zeng2026,
  author = {Zeng, Yue and Zhang, Ting and Cornish, Elisa and Lee, So-Ra and Yam, Michelle and Eminhizer, Mark and Zeng, Jingwen and Zhang, Jialing and Zeng, Shaoxue and Arafah, Azhar Dzulhadj B and Wei, Xian and Yang, Jinliang and Zhu, Meidong and Chang, Andrew and Zhang, Meixia and Du, Jianhai and Zhu, Ling and Gillies, Mark C},
  title = {Dysregulated proline metabolism contributes to retinal fibrosis in neovascular AMD: Therapeutic potential of prolyl-4-hydroxylase inhibition},
  journal = {Molecular Therapy},
  year = {2026},
  volume = {34},
  number = {10},
  pages = {6111--6133},
  doi = {10.1016/j.ymthe.2026.07.044}
}
Kostenlos starten →